Publications by authors named "Raquel Morillo-Guerrero"
Article Synopsis
- Therapeutic-dose heparin may reduce the need for organ support in noncritically ill COVID-19 patients, but its effect on long-term symptoms and quality of life (QOL) is unclear.
- The ACTIV-4a trial randomized 727 hospitalized COVID-19 patients to either therapeutic or prophylactic heparin, with a focus on their symptoms and QOL at a 90-day follow-up using the EQ-5D-5L survey.
- Results indicated that about 50% experienced at least one symptom post-hospitalization, with therapeutic heparin linked to reduced physical impairment, but no significant differences in overall symptoms or QOL scores between the heparin treatment groups.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
N Engl J Med
August 2021
Background: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
Methods: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis.
Risk Of Recurrence After Withdrawal Of Anticoagulation In Patients With Unprovoked Venous Thromboembolism: External Validation Of The Vienna Nomogram And The Dash Prediction Score.
Arch Bronconeumol (Engl Ed)
December 2019
Introduction: Scales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.
View Article and Find Full Text PDFIntroduction: Randomized clinical trials have demonstrated non-inferiority of rivaroxaban compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism (VTE). Our objective was to analyze in real life, tolerance, recurrence, bleeding and adverse events of rivaroxaban in patients with acute symptomatic VTE.
Material And Methods: Open follow-up study of a cohort of patients aged 18 and over diagnosed with deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treated with rivaroxaban from December 2011 to January 2014.
Background And Objective: The predictive Khorana's model was developed to score the thromboembolic disease risk in cancer patients on chemotherapy and to identify which patients would benefit from thromboprophylaxis. We analized the results and applied the predictive Khorana's model in patients with cancer and who were diagnosed with deep vein thrombosis.
Material And Methods: Retrospective analysis of prognostic characteristics of Khorana's model in 122 patients based on a prospective analysis.